This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dhalla, I. A. Articles by Juurlink, D. N. Search for Related Content PubMed PubMed Citation Articles by Dhalla, I. A. Articles by Juurlink, D. N.

Are Broad-Spectrum Fluoroquinolones More Likely To Cause Clostridium difficile-Associated Disease?

Irfan A. Dhalla,^1,8* Muhammad M. Mamdani,^2,7,8, Andrew E. Simor,^1,3,4,5 Alex Kopp,⁸ Paula A. Rochon,^1,6,7,8 and David N. Juurlink^1,4,7,8

Department of Medicine,¹ Department of Pharmacy,² Department of Laboratory Medicine and Pathobiology,³ Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada,⁷ Department of Medicine,⁴ Department of Microbiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada,⁵ Kunin-Lunenfeld Applied Research Unit, Baycrest Research Centre for Aging and the Brain, Toronto, Ontario, Canada,⁶ Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada⁸

Received 14 May 2006/ Returned for modification 11 June 2006/ Accepted 2 July 2006

Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.

Present address: Pfizer, Inc., New York, N.Y.

This article has been cited by other articles:

• Wilcox, M. H., Mooney, L., Bendall, R., Settle, C. D., Fawley, W. N. (2008). A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 0: dkn163v1-9 [Abstract] [Full Text]  
• Mehlhorn, A. J, Brown, D. A (2007). Safety Concerns with Fluoroquinolones. The Annals of Pharmacotherapy 41: 1859-1866 [Abstract] [Full Text]